Drug Trial Radar · NCT07047118
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
138
Actual
Start
Jul 3, 2025
Primary completion
Jul 16, 2027
Study completion May 14, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
Conditions
- Prostatic Cancer, Castration-Resistant
Interventions
JSB462Drug
Administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
AAA617Drug
administered at 7.4 GBq intravenously every 6 weeks for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prostate Specific Antigen 50 (PSA50) RateTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
- Incidence rate of adverse events (AEs)Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
- Number of participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
- Duration of exposure to study treatmentTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
Locations
44 sites in 15 countries. Site status is shown where the registry gives one.
City of Hope National Medical
Duarte, California
Providence Saint Johns Health Ctr
Santa Monica, California
Rocky Mountain Cancer Centers
Denver, Colorado
Yale University School Of Medicine
New Haven, Connecticut
Indiana University
Indianapolis, Indiana
Massachusetts General Hospital
Boston, Massachusetts
XCancer Omaha LLC
Omaha, Nebraska
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York
Univ of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Urology San Antonio
San Antonio, Texas
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Burnaby, British Columbia, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Tours, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Rostock, Germany
Novartis Investigative Site
Afula, Israel
Novartis Investigative Site
Beersheba, Israel
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Jerusalem, Israel
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Hoofddorp, Netherlands
Novartis Investigative Site
Nijmegen, Gerlderland, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.